Researchers presented new findings Saturday at a breast-cancer symposium here suggesting that the risks associated with anthracyclines, a class of chemotherapy drugs widely used to treat the disease, outweighed their benefits in some patients.The findings renewed a debate over whether anthracyclines, which have been around since the 1960s, should remain the standard of care in treating breast cancer, or whether newer drugs should be used more frequently instead.
More...



One of the monkeys that escaped after a truck overturned on a Mississippi roadway on 28...
A civil jury in Maine has awarded $25m to a woman whose teenage daughter died from...





























